Journal
FUTURE ONCOLOGY
Volume 16, Issue 22, Pages 1575-1584Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0280
Keywords
brain metastases; CNS; EGFR; EGFR-TKI; non-small-cell lung cancer; NSCLC; osimertinib; real-world
Categories
Funding
- AstraZeneca, Cambridge, UK, the manufacturer of osimertinib
- AstraZeneca, Cambridge, UK
Ask authors/readers for more resources
Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR mutation-positive (EGFRm) metastatic non-small-cell lung cancer (NSCLC). Materials & methods: This retrospective, observational matched cohort electronic health record study assessed adults with EGFRm metastatic NSCLC with/without BM. Results: Among 402 patients split equally between both cohorts (BM), the majority were Caucasian (69%), female (65%) and with adenocarcinoma (92%). Overall symptom burden and ancillary support service use were higher and median overall survival from metastatic diagnosis was significantly shorter in BM patients (11.9 vs 16 months; p = 0.017). Conclusion: BM in EGFRm NSCLC patients can negatively impact clinical outcomes. New targeted therapies that can penetrate the blood-brain barrier should be considered for treating these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available